Dare Bioscience, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Dare Bioscience, Inc. on September 10, 2026. The report addresses a corporate governance amendment approved by the Board of Directors effective immediately.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a change to the company's bylaws and does not contain financial performance data.
Material Changes
The Board of Directors approved an amendment to the Third Amended and Restated By-Laws. The primary change reduces the quorum requirement for all stockholder meetings:
- Previous Requirement: Holders of a majority in voting power of issued and outstanding shares entitled to vote.
- New Requirement: Holders of at least one-third of the voting power of issued and outstanding shares entitled to vote.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on future performance, risks, contingencies, or unusual items. The document is limited to the procedural amendment of the bylaws.
Key Facts for Investor Verification
- Verify the effective date of the bylaw amendment (September 10, 2026).
- Confirm the new quorum threshold is set at one-third of voting power.
- Review Exhibit 3.1 for the full legal text of the amendment.
- Note that this filing contains no financial results or operational updates.